The influence of ochratoxin A on DNA adduct formation by the carcinogen aristolochic acid in rats

Archives of Toxicology

Volumn 89, Issue 11, 2015, Pages 2141-2158

  Stiborová, Marie ^a   Bárta, František ^a   Levová, Kateřina ^a   Hodek, Petr ^a   Frei, Eva ^b   Arlt, Volker M ^c   Schmeiser, Heinz H ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Aristolochic acid; Aristolochic acid nephropathy; Balkan endemic nephropathy; DNA adducts; Ochratoxin A

Indexed keywords

ARISTOLOCHIC ACID; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C11; OCHRATOXIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); ARISTOLOCHIC ACID I; CARCINOGEN; DNA ADDUCT; NQO1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGEN DNA INTERACTION; CONTROLLED STUDY; DRUG DETOXIFICATION; ENZYME ACTIVATION; ENZYME ACTIVITY; EX VIVO STUDY; GENOTOXICITY; IN VIVO STUDY; KIDNEY MICROSOME; LIVER MICROSOME; MALE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; ANIMAL; DNA ADDUCT; DRUG EFFECTS; DRUG INACTIVATION; KIDNEY; LIVER; METABOLISM; OXIDATION REDUCTION REACTION; WISTAR RAT;

ANIMALS; ARISTOLOCHIC ACIDS; CARCINOGENS; DNA ADDUCTS; INACTIVATION, METABOLIC; KIDNEY; LIVER; MALE; NAD(P)H DEHYDROGENASE (QUINONE); OCHRATOXINS; OXIDATION-REDUCTION; RATS; RATS, WISTAR;

EID: 84947573720     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1360-1     Document Type: Article

References (107)

1. Arlt VM, Pfohl-Leszkowicz A, Cosyns J, Schmeiser HH (2001) Analyses of DNA adducts formed by ochratoxin A and aristolochic acid in patients with Chinese herbs nephropathy. Mutat Res 494:143–150
2. Arlt VM, Stiborova M, Schmeiser HH (2002a) Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17:265–277
3. Arlt VM, Ferluga D, Stiborova M, Pfohl-Leszkowicz A, Vukelic M, Ceovic S, Schmeiser HH, Cosyns JP (2002b) Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer 101:500–502
4. Arlt VM, Stiborova M, vom Brocke J, Simoes ML, Lord GM, Nortier JL, Hollstein M, Phillips DH, Schmeiser HH (2007) Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 28:2253–2261
5. Arlt VM, Levova K, Barta F, Shi Z, Evans JD, Frei E, Schmeiser HH, Nebert DW, Phillips DH, Stiborova M (2011a) Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1-/-, Cyp1a2-/-, and Cyp1a1/1a2-/- mice. Chem Res Toxicol 24:1710–1719
6. Arlt VM, Zuo J, Trenz K, Roufosse CA, Lord GM, Nortier JL, Schmeiser HH, Hollstein M, Phillips DH (2011b) Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. Int J Cancer 128:21–32
7. Bamias G, Boletis J (2008) Balkan nephropathy: evolution of our knowledge. Am J Kidney Dis 52:606–616
8. Bárta F, Levová K, Frei E, Schmeiser HH, Arlt VM, Stiborová M (2014) The effect of aristolochic acid I on NAD(P)H:quinone oxidoreductase expression in mice and rats: a comparative study. Mutat Res 768:1–7
9. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 18:1063–1067
10. Burke MD, Thompson S, Weaver RJ, Wolf CR, Mayer RT (1994) Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol 48:923–936
11. Ceović S, Hrabar A, Radonić M (1985) An etiological approach to Balkan endemic nephropathy based on the investigation of two genetically different populations. Nephron 40:175–179
12. Chen M, Gong L, Qi X, Xing G, Luan Y, Wu Y, Xiao Y, Yao J, Li Y, Xue X, Pan G, Ren J (2011) Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity. Toxicol Sci 122:288–296
13. Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS, Grollman AP (2012) Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA 109:8241–8246
14. Cosyns JP, Jadoul M, Squifflet JP, De Plaen JF, Ferluga D, van Ypersele de Strihou C (1994) Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int 45:1680–1688
15. Cosyns JP, Goebbels RM, Liberton V, Schmeiser HH, Bieler CA, Bernard AM (1998) Chinese herbs nephropathy-associated slimming regimen induces tumours in the forestomach but no interstitial nephropathy in rats. Arch Toxicol 72:738–743
16. Danilovic V, Djurisic M, Mokranjac M, Stojimirovic B, Zivojinovic J, Stojakovic P (1957) Chronic nephritis due to lead poisoning by digestive route (flour) [Néphrites chroniques provoquées par l’intoxication au plomb par voie digestive (farine), in French]. Presse Méd 65:2039–2040
17. De Broe ME (2012) Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy. Kidney Int 81:513–515
18. Debelle FD, Nortier JL, De Prez EG, Garbar CH, Vienne AR, Salmon IJ, Deschodt-Lanckman MM, Vanherweghem JL (2002) Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J Am Soc Nephrol 13:431–436
19. Debelle F, Nortier J, Arlt VM, De Prez E, Vienne A, Salmon I, Phillips DH, Deschodt-Lanckman M, Vanherweghem JL (2003) Effects of dexfenfluramine on aristolochic acid nephrotoxicity in a rat model for Chinese-herb nephropathy. Arch Toxicol 77:218–226
20. Debelle FD, Vanherweghem JL, Nortier JL (2008) Aristolochic acid nephropathy: a worldwide problem. Kidney Int 74:158–169
21. Dinkova-Kostova AT, Talalay P (2010) NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 501:116–123
22. Dinkova-Kostova AT, Fahey JW, Talalay P (2004) Chemical structures of inducers of nicotinamide quinone oxidoreductase 1 (NQO1). Methods Enzymol 382:423–448
23. Djukanović L, Lezaić V, Blagojević R, Radivojević D, Stosović M, Jovanović N, Ristić S, Simić-Ogrizović S (2003) Co-morbidity and kidney graft failure-two main causes of malnutrition in kidney transplant patients. Nephrol Dial Transplant 18(Suppl 5):v68–v70
24. European Food Safety Authority (EFSA) (2006) European Food Safety Authority. Opinion of the scientific panel on contaminants in the food chain of the EFSA on a request from the commission related to ochratoxin A in food. EFSA J 365:1–56
25. Gökmen MR, Cosyns JP, Arlt VM, Stiborová M, Phillips DH, Schmeiser HH, Simmonds MSJ, Look HT, Vanherweghem JL, Nortier JL, Lord GM (2013) The epidemiology, diagnosis and management of aristolochic acid nephropathy: a narrative review. Ann Intern Med 158:469–477
26. Grollman AP, Jelaković B (2007) Role of environmental toxins in endemic (Balkan) nephropathy. J Am Soc Nephrol 18:2817–2823
27. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelic M, Jelakovic B (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 104:12129–12134
28. Hadjeba-Medjdoub K, Tozlovanu M, Pfohl-Leszkowicz A, Frenette C, Paugh RJ, Manderville RA (2012) Structure-activity relationships imply different mechanisms of action for ochratoxin A-mediated cytotoxicity and genotoxicity. Chem Res Toxicol 25:181–190
29. Hoang ML, Chen CH, Sidorenko VS, He J, Dickman KG, Yun BH, Moriya M, Niknafs N, Douville C, Karchin R, Turesky RJ, Pu YS, Vogelstein B, Papadopoulos N, Grollman AP, Kinzler KW, Rosenquist TA (2013) Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med 5:197ra102
30. Hranjec T, Kovac A, Kos J, Mao W, Chen JJ, Grollman AP, Jelaković B (2005) Endemic nephropathy: the case for chronic poisoning by aristolochia. Croat Med J 46:116–125
31. Ivić M (1969) The problem of etiology of endemic nephropathy. Liječ Vjesn 91:1273–1281
32. Jaiswal AK (2000) Regulation of genes encoding NAD(P)H:quinone oxidoreductases. Free Radic Biol Med 29:254–262
33. Jelakovic B, Nikolic J, Radovanovic Z, Nortier J, Cosyns JP, Grollman AP, Basic-Jukic N, Belicza M, Bukvic D, Cavaljuga S, Cvoriscec D, Cvitkovic A, Dika Z, Dimitrov P, Dukanovic L, Edwards K, Ferluga D, Fustar-Preradovic L, Gluhovschi G, Imamovic G, Jakovina T, Kes P, Leko N, Medverec Z, Mesic E, Miletic-Medved M, Miller F, Pavlovic N, Pasini J, Plestina S, Polenakovic M, Stefanovic V, Tomic K, Trnacevic S, Vukovic Lela I, Stern-Padovan R (2013) Consensus statement on screening, diagnosis, classification and treatment of endemic (Balkan) nephropathy. Nephrol Dial Transplant 0:1–9
34. Jelaković B, Karanović S, Vuković-Lela I, Miller F, Edwards KL, Nikolić J, Tomić K, Slade N, Brdar B, Turesky RJ, Stipančić Ž, Dittrich D, Grollman AP, Dickman KG (2012) Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 81:559–567
35. Laursen T, Jensen K, Møller BL (2011) Conformational changes of the NADPH-dependent cytochrome P450 reductase in the course of electron transfer to cytochromes P450. Biochim Biophys Acta 1814:132–138
36. Lebeau C, Debelle FD, Arlt VM, Pozdzik A, De Prez EG, Phillips DH, Deschodt-Lanckman MM, Vanherweghem JL, Nortier JL (2005) Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. Nephrol Dial Transplant 20:2321–2332
37. Levová K, Moserová M, Kotrbová V, Šulc M, Henderson CJ, Wolf CR, Phillips DH, Frei E, Schmeiser HH, Mareš J, Arlt VM, Stiborová M (2011) Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. Toxicol Sci 121:43–56
38. Levová K, Moserova M, Nebert DW, Phillips DH, Frei E, Schmeiser HH, Arlt VM, Stiborová M (2012) NAD(P)H:quinone oxidoreductase expression in Cyp1a-knockout and CYP1A-humanized mouse lines and its effect on bioactivation of the carcinogen aristolochic acid I. Toxicol Appl Pharmacol 265:360–367
39. Long DT, Voice TC (2007) Role of exposure analysis in solving the mystery of Balkan endemic nephropathy. Croat Med J 48:300–311
40. Lord GM, Hollstein M, Arlt VM, Roufosse C, Pusey CD, Cook T, Schmeiser HH (2004) DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis 43:e11–e17
41. Martinek V, Kubickova B, Arlt VM, Frei E, Schmeiser HH, Hudecek J, Stiborova M (2011) Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltransferases. Neuro Endocrinol Lett 32(Suppl 1):57–70
42. Mengs U, Stotzem CD (1993) Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology. Arch Toxicol 67:307–311
43. Miletić-Medved M, Domijan AM, Peraica M (2005) Recent data on endemic nephropathy and related urothelial tumors in Croatia. Wien Klin Wochenschr 117:604–609
44. Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelakovic B, Wu L, Truong S, Fernandes A, Grollman AP (2011) TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer 129:1532–1536
45. Nedelcheva V, Gut I (1994) P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 24:1151–1175
46. Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL (2000) Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342:1686–1692
47. Olivier M, Hollstein M, Schmeiser HH, Straif K, Wild CP (2012) Upper urinary tract urothelial cancer: where it is A:T. Nat Rev 12:503–504
48. Peraica M, Domijan AM, Miletić-Medved M, Fuchs R (2008a) The involvement of mycotoxins in the development of endemic nephropathy. Wien Klin Wochenschr 120:402–407
49. Peraica M, Domijan AM, Sarić M (2008b) Mycotoxic and aristolochic acid theories of the development of endemic nephropathy. Arh Hig Rada Toksikol 59:59–65
50. 32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II. Carcinogenesis 11:1627–1633
51. Pfohl-Leszkowicz A (2009) Ochratoxin A and aristolochic acid involvement in nephropathies and associated urothelial tract tumours. Arh Hig Rada Toksikol 60:465–483
52. Pfohl-Leszkowicz A, Grosse Y, Castegnaro M, Nicolov IG, Chernozemsky IN, Bartsch H, Betbeder AM, Creppy EE, Dirheimer G (1993) Ochratoxin A related DNA adducts. In urinary tract tumours of Bulgarian subjects, IARC Science Publications 124:141–148
53. Pfohl-Leszkowicz A, Petkova-Bocharova T, Chernozemsky IN, Castegnaro M (2002) Balkan endemic nephropathy and associated urinary tract tumours: a review on aetiological causes and the potential role of mycotoxins. Food Addit Contam 19:282–302
54. Pfohl-Leszkowicz A, Tozlovanu M, Manderville R, Peraica M, Castegnaro M, Stefanovic V (2007) New molecular and field evidences for the implication of mycotoxins but not aristolochic acid in human nephropathy and urinary tract tumor. Mol Nutr Food Res 51:1131–1146
55. Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, Weng WH, Siew EY, Liu Y, Heng HL, Chong SC, Gan A, Tay ST, Lim WK, Cutcutache I, Huang D, Ler LD, Nairismägi ML, Lee MH, Chang YH, Yu KJ, Chan-On W, Li BK, Yuan YF, Qian CN, Ng KF, Wu CF, Hsu CL, Bunte RM, Stratton MR, Futreal PA, Sung WK, Chuang CK, Ong CK, Rozen SG, Tan P, Teh BT (2013) Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med 5:197ra101
56. Priestap HA, Torres MC, Rieger RA, Dickman KG, Freshwater T, Taft DR, Barbieri MA, Iden CR (2012) Aristolochic acid I metabolism in the isolated perfused rat kidney. Chem Res Toxicol 25:130–139
57. Pudney CR, Khara B, Johannissen LO, Scrutton NS (2011) Coupled motions direct electrons along human microsomal P450 chains. PLoS Biol 9:e1001222
58. Radovanović Z (2002) Epidemiology and etiology of endemic nephro-pathy. In: Radovanović Z, Sinđi M, Polenaković M, Djukanović Lj, Petronić V (eds) Endemic Nephropathy. Zavod za žbenike i nastavna sredstva. Belgrade, pp. 22–135
59. Ramyaa P, Krishnaswamy R, Padma VV (2014) Quercetin modulates OTA-induced oxidative stress and redox signalling in HepG2 cells—up regulation of Nrf2 expression and down regulation of NF-κB and COX-2. Biochim Biophys Acta 1840:681–692
60. Rendic S, DiCarlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413–480
61. Rosenquist TA, Einolf HJ, Dickman KG, Wang L, Smith A, Grollman AP (2010) Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab Disp 38:761–768
62. Ross D (2004) Quinone reductases multitasking in the metabolic world. Drug Metab Rev 36:639–654
63. Schaaf GJ, Nijmeijer SM, Maas RF, Roestenberg P, de Groene EM, Fink-Gremmels J (2002) The role of oxidative stress in the ochratoxin A-mediated toxicity in proximal tubular cells. Biochim Biophys Acta 1588:149–158
64. Schmeiser HH, Pool BL, Wiessler M (1986) Identification and mutagenicity of metabolites of aristolochic acid formed by rat liver. Carcinogenesis 7:59–63
65. Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP (1996) Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 56:2025–2028
66. 32P-post-labelling: evidence for reductive activation by peroxidases. Carcinogenesis 18:1055–1062
67. Schmeiser HH, Stiborová M, Arlt VM (2009) Chemical and molecular basis of the carcinogenicity of Aristolochia plants. Curr Opin Drug Discov Devel 12:141–148
68. Schmeiser HH, Kucab JE, Arlt VM, Phillips DH, Hollstein M, Gluhovschi G, Gluhovschi C, Modilca M, Daminescu L, Petrica L, Velciov S (2012) Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania. Environ Mol Mutagen 53:636–641
69. 32P-postlabeling analysis of DNA adducts. Methods Mol Biol 1044:389–401
70. Schmeiser HH, Nortier JL, Singh R, Gamboa da Costa G, Sennesael J, Cassuto-Viguier E, Ambrosetti D, Rorive S, Pozdzik A, Phillips DH, Stiborova M, Arlt VM (2014) Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int J Cancer 13:502–507
71. Sistkova J, Hudecek J, Hodek P, Frei E, Schmeiser HH, Stiborova M (2008) Human cytochromes P450 1A1 and 1A2 participate in detoxication of carcinogenic aristolochic acid. Neuro Endocrinol Lett 29:733–737
72. Stefanović V (1983) Diagnostic criteria for endemic (Balkan) nephropathy. In: Strahinjić S, Stefanović V (eds) Current research in endemic (Balkan) nephropathy. University Press, Niš, pp 351–363
73. Stefanović V, Radovanović Z (2008) Balkan endemic nephropathy and associated urothelial cancer. Nat Clin Pract Urol 5:105–112
74. 32P-postlabelling analysis using different chromatographic procedures. Carcinogenesis 15:1187–1192
75. Stiborová M, Frei E, Wiessler M, Schmeiser HH (2001a) Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chem Res Toxicol 14:1128–1137
76. Stiborová M, Hájek M, Vošmiková H, Frei E, Schmeiser HH (2001b) Isolation of DT-diaphorase [NAD(P)H dehydrogenase (quinone)] from rat liver cytosol: identification of new substrates, carcinogenic aristolochic acids. Collect Czech Chem Commun 66:959–972
77. Stiborová M, Frei E, Sopko B, Wiessler M, Schmeiser HH (2002a) Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23:617–625
78. Stiborová M, Martínek V, Rýdlová H, Hodek P, Frei E (2002b) Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res 62:5678–5684
79. Stiborová M, Frei E, Sopko B, Sopková K, Marková V, Lanková M, Kumstýrová T, Wiessler M, Schmeiser HH (2003) Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. Carcinogenesis 24:1695–1703
80. Stiborová M, Frei E, Hodek P, Wiessler M, Schmeiser HH (2005) Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int J Cancer 113:189–197
81. Stiborová M, Dracínská H, Hájková J, Kaderábková P, Frei E, Schmeiser HH, Soucek P, Phillips DH, Arlt VM (2006) The environmental pollutant and carcinogen 3-nitrobenzanthrone and its human metabolite 3-aminobenzanthrone are potent inducers of rat hepatic cytochromes P450 1A1 and -1A2 and NAD(P)H:quinone oxidoreductase. Drug Metab Disp 34:1398–1405
82. Stiborová M, Frei E, Arlt VM, Schmeiser HH (2008a) Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat Res 658:55–67
83. Stiborová M, Frei E, Schmeiser HH (2008b) Biotransformation enzymes in development of renal injury and urothelial cancer caused by aristolochic acid. Kidney Int 73:1209–1211
84. Stiborová M, Mareš J, Frei E, Arlt VM, Martínek V, Schmeiser HH (2011) The human carcinogen aristolochic acid I is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ Mol Mutagen 52:448–459
85. Stiborová M, Levová K, Bárta F, Shi Z, Frei E, Schmeiser HH, Nebert DW, Phillips DH, Arlt VM (2012) Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. Toxicol Sci 125:345–358
86. Stiborová M, Dračínská H, Martínek V, Svášková D, Hodek P, Milichovský J, Hejduková Ž, Brotánek J, Schmeiser HH, Frei E (2013a) Induced expression of cytochrome P450 1A and NAD(P)H:quinone oxidoreductase determined at mRNA, protein, and enzyme activity levels in rats exposed to the carcinogenic azo dye 1-phenylazo-2-naphthol (Sudan I). Chem Res Toxicol 26:290–299
87. Stiborová M, Martínek V, Frei E, Arlt VM, Schmeiser HH (2013b) Enzymes metabolizing aristolochic acid and their contribution to the development of Aristolochic acid nephropathy and urothelial cancer. Curr Drug Metab 14:695–705
88. Stiborová M, Frei E, Arlt VM, Schmeiser HH (2014a) Knock-out and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid. Xenobiotica 44:135–145
89. Stiborová M, Levová K, Bárta F, Sulc M, Frei E, Arlt VM, Schmeiser HH (2014b) The influence of dicoumarol on the bioactivation of the carcinogen aristolochic acid I in rats. Mutagenesis 29:189–200
90. Talalay P, Prochaska HJ (1998) Mechanism of induction of NAD(P)H:quinone reductase. Chem Scr 27A:61–66
91. Tanchev Y, Evstatiev ZV, Dorosiev G, Pencheva ZH, Zvetkov G (1956) Prouchavaniia na nefrititev v vrachanska okolia. [Study on nephritis in the region of Vratza, in Bulgarian]. Savr Med 7:14–29
92. Tatu CA, Orem WH, Finkelman RB, Feder GL (1998) The etiology of Balkan endemic nephropathy: still more questions than answers. Environ Health Perspect 106:689–700
93. Thomas-Schoemann A, Blanchet B, Bardin C, Noé G, Boudou-Rouquette P, Vidal M, Goldwasser F (2014) Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol 89:179–196
94. Toncheva D, Dimitrov T, Stojanova S (1998) Etiology of Balkan endemic nephropathy: a multifactorial disease? Eur J Epidemiol 14:389–394
95. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, Vanhaelen M (1993) Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 341:387–391
96. Večeřa R, Zachařová A, Orolin J, Strojil J, Skottová N, Anzenbacher P (2011) Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat. Biopharm Drug Dispos 32:482–487
97. Vettorazzi A, de Trocóniz IF, González-Peñas E, Arbillaga L, Corcuera LA, Gil AG, de Cerain AL (2011) Kidney and liver distribution of ochratoxin A in male and female F344 rats. Food Chem Toxicol 49:1935–1942
98. Viau C (2002) Biological monitoring of exposure to mixtures. Toxicol Lett 134:9–16
99. Voice TC, Long DT, Radovanović Z, Atkins JL, McElmurry SP, Niagolova ND, Dimitrov P, Petropoulos EA, Ganev VS (2006) Critical evaluation of environmental exposure agents suspected in the etiology of Balkan endemic nephropathy. Int J Occup Environ Health 12:369–376
100. Wiechelman KJ, Braun RD, Fitzpatrick JD (1988) Investigation of the bicinchoninic acid protein assay: identified cation of the groups responsible for color formation. Anal Biochem 175:231–237
101. Yamazaki H, Shimizu M, Nagashima T, Minoshima M, Murayama N (2006) Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of anesthetic agent propofol and deactivated by prior treatment with propofol. Drug Metab Dispos 34:1803–1805
102. Yordanova P, Wilfried K, Tsolova S, Dimitrov P (2011) Ochratoxin A and β2-microglobulin in BEN patients and controls. Toxin (Basel) 2:780–792
103. Yu FY, Wu TS, Chen TW, Liu BH (2011) Aristolochic acid I induced oxidative DNA damage associated with glutathione depletion and ERK1/2 activation in human cells. Toxicol In Vitro 25:810–816
104. Yun BH, Rosenquist TA, Sidorenko V, Iden CR, Chen CH, Pu YS, Bonala R, Johnson F, Dickman KG, Grollman AP, Turesky RJ (2012) Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry. Chem Res Toxicol 25:1119–1131
105. Zachařová A, Siller M, Spičáková A, Anzenbacherová E, Skottová N, Anzenbacher P, Večeřa R (2012) Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. Xenobiotica 42:731–736
106. Zaied C, Bouaziz C, Azizi I, Bensassi F, Chour A, Bacha H, Abid S (2011) Presence of ochratoxin A in Tunisian blood nephropathy patients. Exposure level to OTA. Exp Toxicol Pathol 63:613–618
107. Zhu S, Wang Y, Jin J, Guan C, Li M, Xi C, Ouyang Z, Chen M, Qiu Y, Huang M, Huang Z (2012) Endoplasmic reticulum stress mediates aristolochic acid I-induced apoptosis in human renal proximal tubular epithelial cells. Toxicol In Vitro 26:663–671